BV-FAPESP: research projects supported in this Center
OCRC in the Media: news about the Center
The Obesity and Comorbidities Research Center (OCRC) is one of the Research, Innovation and Dissemination Centers (RIDC) supported by FAPESP, and is active since June 2013.
OCRC coordinates scientific efforts to find solutions for obesity, a disease highly associated with a number of serious health problems such as type 2 diabetes, hypertension, atherosclerosis, and certain kinds of cancer. The overall mortality directly and indirectly associated with obesity is rapidly increasing in Brazil and all around the world – so much so that, today, it is considered a global epidemic.
The OCRC staff is constantly in contact with the industry and other potential users of the knowledge and products obtained through our research in order to speed up the transfer of knowledge to society.
In a study conducted at a FAPESP-funded research center, a bile acid derivative known by the acronym TUDCA reduced food intake and increased energy expenditure in mice, improving quality of life. The results are promising for humans.
In an article published in PLOS ONE, scientists at a FAPESP-supported research center describe the impact of hypoproteinemia on the expression of microRNAs associated with kidney development in rat embryos.
Researchers at the University of Campinas in Brazil reveal the mechanisms whereby SARS-CoV-2 disrupts the regulation of inflammation, coagulation and blood pressure when it infects alveolar cells, responsible for gas exchange in the lungs.
Led by research groups from the universities of Campinas and São Paulo, the investigation combined MRI scans of mild COVID-19 patients, analysis of brain tissue samples from patients who died from COVID-19, and experiments performed with human nerve cells infected in the laboratory.
Brazilian researchers are the only Latin American group to have had a project selected in an international request for applications by the Chan Zuckerberg Initiative. Funding of more USD 175,000 has been awarded to the study, which will be the first in Brazil to use single-cell analysis.
One of the studies will evaluate the effectiveness of drugs that inhibit bradykinin against pulmonary inflammation in critical patients. The other will analyze the transmission dynamics of the novel coronavirus in a small town in Amazonia.